Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis.
Apremilast
efficacy
psoriasis
real-world
safety
Journal
Indian dermatology online journal
ISSN: 2229-5178
Titre abrégé: Indian Dermatol Online J
Pays: India
ID NLM: 101586880
Informations de publication
Date de publication:
Historique:
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
15
2
2020
Statut:
epublish
Résumé
Apremilast is the new oral drug in the management of moderate-to-severe plaque psoriasis with well-established effectiveness and safety in long-term clinical trials and a few real-world studies. However, its effectiveness and safety in Indian setup have not been reported yet. This was retrospective, single-center, longitudinal, observational cohort study where the total study period was 24 weeks. Effectiveness parameters were the proportion of patients achieving psoriasis area and severity index (PASI) 50, 75, 90, and 100 response at week 16 and 24. Safety was measured as the proportion of patients reporting ≥1 adverse event (AE) during the study period. Data of a total of 70 patients were included in our study. At week 16, 76.92%, 41.53%, 15.38%, and 6.15% patients achieved PASI 50, 75, 90, and 100, respectively. At week 24, 81.53%, 58.46%, 29.23%, and 10.76% patients achieved PASI 50, 75, 90, and 100, respectively. Mean percentage reduction in PASI was 67% at week 24 and DLQI score was reduced significantly to 3.4 from mean baseline DLQI score of 10.8 ( The results of this study support the long-term use of apremilast monotherapy as an efficacious and safe treatment option for the management of moderate-to-severe plaque psoriasis.
Identifiants
pubmed: 32055509
doi: 10.4103/idoj.IDOJ_169_19
pii: IDOJ-11-51
pmc: PMC7001393
doi:
Types de publication
Journal Article
Langues
eng
Pagination
51-57Informations de copyright
Copyright: © 2020 Indian Dermatology Online Journal.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Can Fam Physician. 2017 Apr;63(4):278-285
pubmed: 28404701
J Am Acad Dermatol. 2015 Jul;73(1):37-49
pubmed: 26089047
J Am Acad Dermatol. 2018 Mar;78(3):623-626
pubmed: 28989112
Drugs. 2015 Aug;75(12):1393-403
pubmed: 26220911
J Dermatolog Treat. 2019 Jun;30(4):383-386
pubmed: 30221571
J Cutan Med Surg. 2018 May/Jun;22(3):290-296
pubmed: 29373924
J Am Acad Dermatol. 2011 Jul;65(1):137-74
pubmed: 21306785
J Cutan Med Surg. 2017 Mar/Apr;21(2):145-151
pubmed: 27846617
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1173-1179
pubmed: 29388335
J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2002-10
pubmed: 25885420
J Investig Dermatol Symp Proc. 2004 Mar;9(2):140-7
pubmed: 15083781
Am J Clin Dermatol. 2012 Dec 1;13(6):365-74
pubmed: 22967166
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
pubmed: 15083780
J Am Acad Dermatol. 2014 May;70(5):871-81.e1-30
pubmed: 24576585
Drugs. 2012 Oct 1;72(14):1867-80
pubmed: 22938141
JAMA Dermatol. 2013 Oct;149(10):1180-5
pubmed: 23945732
J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:2-11
pubmed: 21388453
Clin Exp Dermatol. 2017 Aug;42(6):675-676
pubmed: 28621002
Indian Dermatol Online J. 2016 Nov-Dec;7(6):471-480
pubmed: 27990381
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
J Am Acad Dermatol. 2009 Sep;61(3):451-85
pubmed: 19493586
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517
pubmed: 27768242
J Am Acad Dermatol. 2001 Nov;45(5):649-61; quiz 662-4
pubmed: 11606913
J Am Acad Dermatol. 2009 Feb;60(2):218-24
pubmed: 19022533
Arch Dermatol. 2012 Jan;148(1):95-102
pubmed: 22250239
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):254-259
pubmed: 28925560
Lancet. 2003 Apr 5;361(9364):1197-204
pubmed: 12686053
Br J Dermatol. 2015 Dec;173(6):1387-99
pubmed: 26357944